✦ LIBER ✦

Improving Second-Line Therapy in Aggressive Non-Hodgkin’s Lymphoma

✍ Scribed by Christian Gisselbrecht; Nicolas Mounier

Book ID: 114473435
Publisher: Elsevier Science
Year: 2004
Tongue: English
Weight: 82 KB
Volume: 31
Category: Article
ISSN: 0093-7754
DOI: 10.1053/j.seminoncol.2003.12.004

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Dose-dense therapy improves survival in

Dose-dense therapy improves survival in aggressive non-Hodgkin’s lymphoma

✍ Michael A. Fridrik; Hubert Hausmaninger; Alois Lang; Johannes Drach; Otto Kriege 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 174 KB

Dexamethasone, etoposide, ifosfamide, an

Dexamethasone, etoposide, ifosfamide, and cisplatin as second-line therapy in patients with aggressive non-hodgkin's lymphoma

✍ Nissim Haim; Menachem Ben-Shahar; David Faraggi; Avital Tsuri-Etzioni; Michelle 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 85 KB 👁 2 views

## BACKGROUND. This study analyzed the long term results of a combination of dexa-

Early therapy monitoring with FDG-PET in

Early therapy monitoring with FDG-PET in aggressive non-Hodgkin’s lymphoma and Hodgkin’s lymphoma

✍ Tatsuo Torizuka; Fumitoshi Nakamura; Toshihiko Kanno; Masami Futatsubashi; Etsuj 📂 Article 📅 2004 🏛 Springer 🌐 English ⚖ 282 KB

Second malignancies in non-Hodgkin's lym

Second malignancies in non-Hodgkin's lymphoma

✍ Brendan K. Macdougall; Brian H. Weinerman; Samuel Kemel 📂 Article 📅 1981 🏛 John Wiley and Sons 🌐 English ⚖ 309 KB 👁 2 views

Prognostic factors in patients with aggr

Prognostic factors in patients with aggressive non-Hodgkin’s lymphoma without complete response to first-line therapy

✍ Suleyman Alici; Sevil Bavbek; Mert Basaran; Haluk Onat 📂 Article 📅 2006 🏛 Springer Healthcare Communications 🌐 English ⚖ 278 KB

HOAP-Bleo as salvage therapy for diffuse

HOAP-Bleo as salvage therapy for diffuse aggressive non-Hodgkin's lymphoma

✍ R. Liang; D. Todd; T. K. Chan 📂 Article 📅 1988 🏛 Springer 🌐 English ⚖ 254 KB

A total of 30 patients with recurrent or unresponsive diffuse, aggressive non-Hodgkin's lymphoma, who had previously received doxorubicin, cyclophosphamide, vincristine, and prednisone with or without bleomycin were treated with a combination of doxorubicin, vincristine, ara C, prednisone, and bleom